Aptevo Therapeutics (NASDAQ:APVO) Now Covered by StockNews.com

StockNews.com started coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a research report released on Friday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Aptevo Therapeutics Price Performance

APVO stock opened at $0.39 on Friday. Aptevo Therapeutics has a 1 year low of $0.36 and a 1 year high of $7.20. The firm has a 50-day moving average of $0.68 and a 200 day moving average of $1.36.

Aptevo Therapeutics (NASDAQ:APVO) last released its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($1.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.11). On average, sell-side analysts expect that Aptevo Therapeutics will post -2.37 EPS for the current fiscal year.

Hedge Funds Weigh In On Aptevo Therapeutics

Institutional investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP bought a new position in shares of Aptevo Therapeutics during the fourth quarter valued at approximately $29,000. Virtu Financial LLC bought a new position in shares of Aptevo Therapeutics during the second quarter valued at approximately $46,000. Citadel Advisors LLC bought a new position in shares of Aptevo Therapeutics during the third quarter valued at approximately $51,000. Bank of New York Mellon Corp bought a new position in shares of Aptevo Therapeutics during the first quarter valued at approximately $152,000. Finally, Renaissance Technologies LLC increased its stake in shares of Aptevo Therapeutics by 18.7% during the second quarter. Renaissance Technologies LLC now owns 69,886 shares of the biotechnology company’s stock valued at $250,000 after purchasing an additional 11,000 shares in the last quarter. 8.06% of the stock is owned by institutional investors.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and.